關鍵數據
7.980今開
7.980最高
484.88K成交量
10.14本益比TTM
2.24本益比動
0.137股利TTM
0.19%換手率
8.200昨收
7.710最低
2.65M成交額
11.97本益比靜
0.33市淨率
1.74%股息率 TTM
2.48%ROA
11.14052週最高
0.47量比
169.72M淨利潤
258.22M總股本
0.7760每股盈餘TTM
0.66Beta
7.67%ROE
7.39052週最低
3.29%振幅
36.47%毛利率
2.03B總市值
9.27回報/風險
1.55%風險率
操作建議
Grifols SA當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名48/155位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為11.73。中期看,股價處於平穩狀態。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Grifols SA新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Grifols SA簡介
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
公司代碼GRFS
公司Grifols SA
CEOAbia (Jose Ignacio)
網址https://www.grifols.com/
公司股東
常見問題
Grifols SA(GRFS)的當前股價是多少?
Grifols SA(GRFS)的當前股價是 7.88。
Grifols SA股票的52週最高點是11.14。
Grifols SA股票的52週最低點是7.39。
現在Grifols SA(GRFS)的股票是買入、持有還是賣出?
根據分析師評級,Grifols SA(GRFS)的總體評級為買入,目標價格為11.73。
Grifols SA(GRFS)股票的每股收益(EPS TTM)是多少
Grifols SA(GRFS)股票的每股收益(EPS TTM)是0.67。